Faculty, Staff and Student Publications
Publication Date
4-1-2024
Journal
Cancer Treatment Reviews
DOI
10.1016/j.ctrv.2024.102720
PMID
38502995
Abstract
Antibody drug conjugates (ADCs) are an emerging class of treatments designed to improve efficacy and decrease toxicity compared with other systemic therapies through the selective delivery of cytotoxic agents to tumor cells. Datopotamab deruxtecan (Dato-DXd) is a novel ADC comprising a topoisomerase I inhibitor payload and a monoclonal antibody directed to trophoblast cell-surface antigen 2 (TROP2), a protein that is broadly expressed in several types of solid tumors. Dato-DXd is being investigated across multiple solid tumor indications. In the ongoing, first-in-human TROPION-PanTumor01 phase I study (ClinicalTrials.gov: NCT03401385), encouraging and durable antitumor activity and a manageable safety profile was demonstrated in patients with advanced/metastatic hormone receptor-positive/human epidermal growth factor receptor2-negative breast cancer (HR+/HER2- BC), triple-negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC). Improved understanding of the adverse events (AEs) that are associated with Dato-DXd and their optimal management is essential to ensure safe and successful administration. Interstitial lung disease/pneumonitis, infusion-related reactions, oral mucositis/stomatitis, and ocular surface events have been identified as AEs of special interest (AESIs) for which appropriate prevention, monitoring, and management is essential. This article summarizes the incidence of AESIs among patients with HR+/HER2- BC, TNBC, and NSCLC reported in TROPION-PanTumor01. We report our recommendations for AESI prophylaxis, early detection, and management, using experience gained from treating AESIs that occur with Dato-DXd in clinical trials.
Keywords
Humans, Female, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Lung Neoplasms, Antineoplastic Agents, Immunoconjugates, Trastuzumab, Breast Neoplasms, Receptor, ErbB-2, Camptothecin, Clinical Trials, Phase I as Topic
Published Open-Access
yes
Recommended Citation
Heist, Rebecca S; Sands, Jacob; Bardia, Aditya; et al., "Clinical Management, Monitoring, and Prophylaxis of Adverse Events of Special Interest Associated With Datopotamab Deruxtecan" (2024). Faculty, Staff and Student Publications. 4820.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4820
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons